Anthony Y H Lu
Overview
Explore the profile of Anthony Y H Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Q, Lu A
Pharmacol Rev
. 2011 Mar;
63(2):437-59.
PMID: 21436344
Individual variability in drug efficacy and drug safety is a major challenge in current clinical practice, drug development, and drug regulation. For more than 5 decades, studies of pharmacogenetics have...
2.
Khojasteh S, Prabhu S, Kenny J, Halladay J, Lu A
Eur J Drug Metab Pharmacokinet
. 2011 Feb;
36(1):1-16.
PMID: 21336516
The majority of marketed small-molecule drugs undergo metabolism by hepatic Cytochrome P450 (CYP) enzymes (Rendic 2002). Since these enzymes metabolize a structurally diverse number of drugs, metabolism-based drug-drug interactions (DDIs)...
3.
Tang W, Lu A
Drug Metab Rev
. 2009 Nov;
42(2):225-49.
PMID: 19939207
Retrospective studies indicate that many drugs that cause clinical adverse reactions, such as hepatotoxicity, undergo metabolic bioactivation, resulting in the formation of electrophilic intermediates capable of covalently modifying biological macromolecules....
4.
Tang W, Lu A
Curr Pharm Des
. 2009 Jul;
15(19):2170-83.
PMID: 19601821
Pharmacokinetics has been recognized as one of the elements determining the probability of success in pharmaceutical research. As a result, compounds are routinely evaluated in drug discovery for their absorption,...
5.
Shou M, Lu A
Drug Metab Dispos
. 2009 Feb;
37(5):925-31.
PMID: 19196844
Cytochrome P450 (P450) is the superfamily of enzymes responsible for biotransformation of endobiotics and xenobiotics. However, their large isoform multiplicity, inducibility, diverse structure, widespread distribution, polymorphic expression, and broad overlapping...
6.
Ma Q, Lu A
Curr Drug Metab
. 2008 Jun;
9(5):374-83.
PMID: 18537574
Unlike classical enzymes, drug-metabolizing enzymes (DMEs), such as the liver microsomal cytochrome P450, UDP-glucuronyltransferase, epoxide hydrolase, and flavin-containing monooxygenase, all exhibit broad substrate specificities, low turnover rates, atypical kinetics, and...
7.
Lambert J, Sang S, Lu A, Yang C
Curr Drug Metab
. 2007 Jun;
8(5):499-507.
PMID: 17584021
Polyphenolic compounds are abundant in the human diet and gram quantities are ingested daily. The consumption of polyphenols is expected to rise due to the use of dietary supplements and...
8.
Ma Q, Lu A
Drug Metab Dispos
. 2007 Apr;
35(7):1009-16.
PMID: 17431034
CYP1A1 and 1A2 play critical roles in the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines/amides (HAAs), respectively, to electrophilic reactive intermediates, leading to toxicity and...
9.
Tang W, Wang R, Lu A
Curr Drug Metab
. 2005 Oct;
6(5):503-17.
PMID: 16248842
An important role of human cytochrome P450s (P450s) has been well recognized in the area of drug metabolism and pharmacokinetics. It has become possible in recent years to express catalytically...
10.
Tang C, Lin J, Lu A
Drug Metab Dispos
. 2005 Jan;
33(5):603-13.
PMID: 15673596
Individual variability in cytochrome P450 (P450) induction comprises an important component contributing to the difficulties in assessing and predicting metabolism-based drug-drug interactions in humans. In this article, we outline the...